PTGX
Protagonist Therapeutics, Inc.
$134.44
+4.42% 2026-10-19
Health CareS&P 600
PTGXSPY
1W
-7.2%
1M
-6.0%
3M
+0.1%
6M
+27.5%
YTD
+53.9%
1Y
+73.5%
Live chart
Loading live chart…
Grades vs sector
Momentum91st pct in sectorA
Momentum
91st pct in sector
12-1 return: +79.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth99th pct in sectorA+
Growth
99th pct in sector
Revenue growth (YoY): +3749.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value2nd pct in sectorF
Value
2nd pct in sector
Forward E/P: – · EBITDA/EV: 0.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability72nd pct in sectorB
Profitability
72nd pct in sector
Profit margin: +29.4% · Return on equity: +11.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$8.7B
P/E (trailing)130.5
P/E (forward)-878.1
52-week range73.08 – 160.81
Revenue growth (YoY, latest qtr)+3749.2%
Dividend yield0.00%
Analyst consensusStrong Buy (14)
Mean price target$178.21 (+33%)
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-05 · during market · EPS est 2.53
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | 1.94 | 2.29 | +18.3% |
| 2026-05-05 | -0.65 | 0.05 | +107.6% |
| 2026-02-25 | -0.54 | -0.69 | -27.4% |
| 2025-11-06 | -0.64 | -0.62 | +3.6% |
| 2025-08-06 | -0.52 | -0.55 | -4.8% |
| 2025-05-06 | 0.11 | -0.19 | -272.7% |
| 2025-02-21 | 0.25 | 1.98 | +692.0% |
| 2024-11-07 | -0.53 | -0.54 | -1.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $213.5M | +3749.2% |
| 2026-03-31 | $56.4M | – |
| 2025-12-31 | $7.4M | – |
| 2025-09-30 | $4.7M | – |
| 2025-06-30 | $5.5M | – |
Analyst actions
UBS
PT $184
2026-10-12 · init
→ BuyPT $184
Barclays
PT $180
2026-09-01 · main
Overweight → OverweightPT $180
BMO Capital
PT $190
2026-09-01 · main
Outperform → OutperformPT $190
Citigroup
PT $182
2026-08-31 · main
Buy → BuyPT $182
HC Wainwright & Co.
PT $170
2026-08-31 · main
Buy → BuyPT $170
BMO Capital
PT $178
2026-08-17 · main
Outperform → OutperformPT $178
Insider trades
Ali Asif
$1.8M
Chief Financial Officer · 2026-09-30
SELL$1.8M
Ali Asif
$6.5M
Chief Financial Officer · 2026-09-30
SELL$6.5M
Patel Dinesh V Ph D
$1.0M
Director, President and CEO · 2026-09-10
SELL$1.0M
Patel Dinesh V Ph D
$9.3M
Director, President and CEO · 2026-09-09
SELL$9.3M
Patel Dinesh V Ph D
$7.9M
Director, President and CEO · 2026-09-08
SELL$7.9M
Patel Dinesh V Ph D
$5.1M
Director, President and CEO · 2026-08-11
SELL$5.1M
Patel Dinesh V Ph D
$9.8M
Director, President and CEO · 2026-08-10
SELL$9.8M
None
–
None · None
SELL–
News
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
Zacks · Oct 15
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target
MT Newswires · Oct 12
The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal · Sep 25
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
GlobeNewswire · Sep 21
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Zacks · Sep 18
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
MT Newswires · Sep 11
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire · Sep 08
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey · Sep 06
Stats refreshed 2026-10-19 19:02:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.